The Claim
In adolescents with obesity and type 2 diabetes, 36 weeks of weekly Mazdutide 6 mg combined with metformin and insulin is associated with a 69.02% reduction in triglycerides and a 17.27% reduction in LDL cholesterol.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In teenagers with obesity and type 2 diabetes, a combination of weekly Mazdutide 6 mg, metformin, and insulin for 36 weeks was linked to a 69.02% drop in triglycerides and a 17.27% drop in LDL cholesterol.
See the scientific wording
In an adolescent with obesity and type 2 diabetes, 36 weeks of weekly Mazdutide 6 mg combined with metformin and insulin was associated with a 69.02% reduction in triglycerides and a 17.27% reduction in LDL cholesterol, suggesting potential benefit for dyslipidemia in this population.
A drug that activates two receptors in the body — one that boosts insulin and reduces hunger, and another that tells the liver to burn fat — causes the liver to stop making excess fat and start burning stored fat instead. This reduces the amount of fat released into the blood, lowering both triglycerides and LDL cholesterol.
What the research says
1 studyA teen with obesity and diabetes took a weekly shot called Mazdutide along with his other medicines, and after 36 weeks, his bad blood fats dropped a lot — just like the claim said.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.